Streetbeat News

Analyst Ratings

DLB

Rosenblatt analyst Steve Frankel has reiterated a 'Buy' rating on Dolby Laboratories (NYSE:DLB) and maintained a price target of $93.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 12:05 pm

PEGA

Rosenblatt analyst Blair Abernethy has reiterated a 'Buy' rating on Pegasystems (NASDAQ:PEGA) and maintained a price target of $62.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 12:02 pm

PIPR

Piper Sandler (NYSE:PIPR) reported Q2 earnings of $1.13 per share, missing the analyst consensus estimate of $1.15 by 1.74%. This is a 54.25% decrease from the same period last year. However, the company's quarterly sales of $288.73 million beat the analyst consensus estimate of $274.00 million by 5.37%, despite being an 18.02% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 12:01 pm

INTC

Rosenblatt analyst Hans Mosesmann has reiterated a 'Sell' rating on Intel (NASDAQ:INTC) and maintained a price target of $17.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 12:01 pm

FIXX

In the last quarter, Homology Medicines (NASDAQ:FIXX) received two bullish and two indifferent analyst ratings. Over the past three months, four analysts have offered 12-month price targets for the company, with an average price target of $7.62, representing a 10.35% decrease from the previous average price target of $8.50.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 12:01 pm

VLY

Analysts have provided ratings for Valley Ntl (NASDAQ:VLY) within the last quarter, with one somewhat bullish rating and three indifferent ratings. The average price target is $9.25, which is lower than the current price of $10.04, implying a downside. This average price target has increased by 2.78% over the past month.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 12:01 pm

SAM

Boston Beer Co (NYSE:SAM) has received mixed analyst ratings in the last quarter, with 1 bullish, 4 indifferent, and 1 bearish. The average price target is $331.17, indicating an upside from the current price of $313.52. The average price target has increased by 10.3% over the past month.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 12:00 pm

IART

Over the last quarter, Integra Lifesciences (NASDAQ:IART) has received mixed analyst ratings. The average price target is $49.89, which is higher than the current price of $44.54. However, this represents an 11.89% decrease from the previous average price target of $56.62.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 12:00 pm

ICLR

Icon (NASDAQ:ICLR) has received various analyst ratings in the last quarter, with 2 bullish, 2 somewhat bullish, and 1 indifferent. The average price target is $268.8, compared to the current price of $241.64, implying an upside. The average price target has increased by 2.99% over the past month.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 12:00 pm

FSK

FS KKR Capital (NYSE:FSK) has received one bullish rating and four indifferent ratings from analysts in the last quarter. The average price target for the stock is $20.5, which is slightly above its current price of $20.07. This average price target has increased by 8.58% from the previous average of $18.88.

Portfolio Pulse from Benzinga Insights

July 28, 2023 | 12:00 pm